Canada: A Medical Device Has Its Day In Court - Andersen v. St. Jude Medical

Edited by James Tumbridge

On June 26, 2012, the Ontario Superior Court released its much-anticipated decision in Andersen et al. v. St. Jude Medical, Inc. et al. http://canlii.ca/t/frtzt.

The proceeding, a product liability class action involving the safety of mechanical prosthetic heart valves and annuloplasty rings coated with Silzone, was first certified in 2003.  Some nine years later, it has become the first class action in Canada involving a pharmaceutical drug or medical device to go the distance – a common issue trial resulting in a judgment with Reasons for Decision.

The essential allegation in the common issues trial was that the devices were unsafe and negligently designed. The devices were recalled from the Canadian market in 2000. The trial was lengthy and complex. It lasted 138 court days conducted over 18 months, involved almost 2300 documents, heard from 40 witnesses (23 of whom were experts from 14 different scientific and medical disciplines), and resulted in the submission of written argument briefs in the hundreds of pages. At the conclusion of the marathon trial, Justice Lax decided that the action should be dismissed.

Although there were nine common issues before the trial court, the Decision focused on breach of duty and causation. The Court examined the Defendants' conduct in designing, testing and marketing the Silzone valve (Common Issue 1). It considered issues of general causation, including whether Silzone had an adverse effect on tissue healing (Common Issue 2). It assessed whether the risk of medical complications for patients with Silzone valves was greater than the risk associated with the use of other devices (Common Issue 3). The other common issues largely dealt with remedies which, given that the proceeding was dismissed, proved to be irrelevant.

Breach in Premarket Design, Manufacture or Testing

At common law in Canada, a manufacturer is required to perform a risk-utility assessment when designing and testing a product, and is required to use reasonable care in doing so. This assessment involves weighing both the gravity and likelihood of reasonably foreseeable risks relative to the overall utility of the product in question. In Andersen, Justice Lax found that the evidence demonstrated that the pre-market design and testing of the devices by the Defendants met the required standard of care. In doing so, she relied on both the expert evidence and the evidence that Silzone devices met industry and regulatory standards (as implicitly demonstrated by both the U.S. FDA and Health Canada approvals). 

Breach in Post-Market Surveillance, Warning and Recall

Justice Lax held that because a device manufacturer is the expert on its own product, it has a continuing duty to inform physicians when dangerous side-effects concerning its products are discovered. In the case of the Silzone valve, warnings about the relevant side-effects were contained in the product labelling. The product was eventually recalled. The issue at trial therefore focused on whether the timing of the recall was reasonable in the circumstances.

Justice Lax found that the risk of complications was not materially increased by the Silzone valve when compared to the risk of complications in similar devices. For the sake of completeness, however, she also held that the evidence demonstrated that the Defendants effectively investigated complaints and that the information available up to the date of the recall supported a reasonable belief that the valve posed no additional risk.

Effect of the Valve Coating on Tissue Healing

The general causation issue concerned an analysis of the Silzone coating material, of which silver was an ingredient. The Court held that there was no reliable evidence in support of the Plaintiffs' theory that silver was toxic or of the mechanism by which the coating interfered with healing of, or caused damage to, existing heart tissue.

The Court also examined whether Silzone devices created a statistically greater risk to patients based on an examination of epidemiological evidence. Justice Lax held that where epidemiological evidence demonstrated a "doubling" of risk of complications above those created by other devices, individual causation could be presumptively proven on a balance of probabilities, absent evidence to rebut that presumption. On the other hand, where the evidence demonstrated a statistically lesser increase in risk, individual causation was presumptively disproved, absent individual evidence to rebut that presumption. In other words, the "doubling of risk" threshold based on epidemiological evidence determined who had the burden of proving individual causation.

In reviewing the evidence, Justice Lax adopted the "recognized hierarchy" of reliability for medical studies: most reliable, randomized control trials; next, cohort studies (or non-randomized observational studies); and last, reported case series. Importantly, Justice Lax rejected the Plaintiffs' assertion, based on cases such as Snell v. Farrell, [1990] 2 S.C.R. 311 (S.C.C.), that she should take a "robust and pragmatic" approach to the evidence and that she should make an inference of causation based on "the totality of the evidence" in the absence of reliable scientific evidence.  In the result, Justice Lax ruled, with a few narrow exceptions, that Silzone did not materially increase the risk of complications. 

Waiver of Tort

In product liability cases brought in Ontario after pronouncement of Serhan Estate v. Johnson & Johnson, 2004 CanLII 1533 (ON SC); 2006 CanLII 20322 (ON SCDC), plaintiffs have typically invoked the doctrine of "waiver of tort."  By doing so, they propose to give up the right to sue and recover damages in tort, if any, and instead seek recovery on the basis of restitution, claiming disgorgement of the revenues or profits gained by a wrongdoer from their wrongful conduct. A crucial but unresolved aspect of the doctrine of waiver of tort is whether its application requires proof of all elements or an underlying tort, or whether it is capable of being asserted as an independent cause of action. In previous decisions, Ontario courts declined to resolve the issue on the basis that adjudication of such an important point should only be made with the benefit of a "full factual record" such as that secured through trial.  

While a full record was before Justice Lax on waiver of tort, she declined to resolve the issue given her conclusion that there was no liability.  She did, however, make several statements on the significance of the issue as well as opining on the nature of the factual record required for resolution of the waiver of tort issue. This included a statement that analysis of waiver of tort involved "philosophical and policy considerations" that did not require a trial for resolution, seemingly in contradiction to obiter dicta in earlier appellate decisions.  Justice Lax observed: "the fundamental question for a Court to answer is whether the recognition (or not) of the waiver of tort doctrine is within the capacity of a Court to resolve, or whether it has such far reaching and complex effects that is best left to consideration by the legislature." Hopefully, this statement will spur Ontario courts to resolve the waiver of tort issue without the necessity of a full trial, which will give much needed clarity.  

Important Implications from the Decision

The Andersen v. St. Jude Medical Inc. case demonstrates that the requirement to establish all elements of negligence against a manufacturer is alive and well in common law Canada. When dealing with causation, Justice Lax cited authority for the proposition that plaintiffs must establish "if only by the slimmest balance of probability, that a named cause is likely. To demonstrate a possibility is not enough; probability must be established."

The Decision also asserts that when a manufacturer conducts testing that is reasonable and that is in accordance with international standards, and in the absence of any scientific literature that casts doubt on the safety of a new product, the court should be reluctant to impose liability on the manufacturer. The court will look to materials or standards published by regulatory authorities such as Health Canada, the FDA, ISO, etc., in assessing the adequacy of testing conducted by a manufacturer.

Furthermore, even if a specific product design or attribute materially increases the risk of a medical complication, the plaintiffs have the burden of establishing that such increased risk is attributable to some act or omission by a manufacturer that falls below the applicable standard of care. It will be insufficient for plaintiffs merely to make allegations to satisfy their burden. Plaintiffs will have to discharge their onus by leading evidence to demonstrate specifically what different and/or more extensive pre-clinical and clinical studies would have been required before the product was marketed. 

While a manufacturer may be required to undertake a risk-benefit analysis in relation to a new product, and is thereby required to weigh both the gravity and likelihood of a reasonably foreseeable risk relevant to the potential extent of a product's utility, liability can be avoided. In conducting its risk-benefit analysis, a manufacturer is not required to assess whether the benefits of the putative "improvement" outweigh the benefits of the existing therapy, but rather, whether the potential benefits associated with the putative improvement outweigh the potential risks of the improvement.

Moreover, where a regulator approves a device (or drug) based on specific data, the court will not second-guess the regulator or the manufacturer provided its decision is reasonable: for example, where there is no suitable pre-marketing evaluation process available to assess the concern. 

As to general causation, if available data involves small numbers, and especially where a 'control' group is absent, no conclusions as to cause-and-effect can be drawn.  This finding has important consequences as to the nature of scientific evidence that must be adduced in a drug or device case to enable a court to conclude general causation in the plaintiffs' favour.  Other indicia of causation in a medical context must be present (for example, biological plausibility). 

Thus, causation cannot be determined merely by examining a series of clinical case reports and concluding, for example, that the complication alleged with the St. Jude valve was caused by the Silzone coating. This finding applies even where there are a higher number of reports of complication in the patients who received Silzone-coated artificial valves than in those who received uncoated, but otherwise identical, artificial valves. To establish cause-and-effect or to establish that the putative cause "materially" increases the risk of the alleged adverse effect, the plaintiffs will be obliged to adduce credible epidemiologic evidence - the kind of epidemiologic studies and investigations at the higher end of the recognized hierarchy of epidemiological studies in the scientific literature.

Importantly, however, Justice Lax found that even where the quality of epidemiologic evidence is sound, it does not mean that all patients who suffered the alleged adverse effect would not have suffered it 'but for' the putative cause.  This means that epidemiologic evidence alone cannot and does not establish 'specific causation' (i.e., that the alleged side effect was caused by the putative cause in the case of any individual patient).   This finding will have material impact on arguing against class certification in product liability cases involving allegations of personal injury.

Lastly, the Court affirmed the generally recognized increase of 2.0 or greater in risk ratio required by the (predominantly U.S.) jurisprudence to establish cause-and-effect based on epidemiological evidence. The Court observed, however, that because defendants retain the right to rebut individual causation (whether the device caused plaintiff's specific injury) even where the risk ratio is greater than 2.0, there is an implicit acknowledgement that individualized causation evidence must be adduced at the individual stage of proceedings following the common issues trial.

The trial decision in Andersen v St. Jude Medical Inc., released on June 26, 2012, coupled with the decision of  C. Horkins  J. in Martin v. Astrazeneca Pharmaceuticals Plc, 2012 ONSC 2744 released on May 7, 2012 declining class certification, could well mark a significant change in fortune for defendants in pharmaceutical and medical device class actions in Ontario, and inferentially in the common law provinces of Canada. We will be watching closely for any appellate review of the decisions. It seems, however, that manufacturers can take comfort finally that the tide has turned for their class action risk in Canada.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Osler, Hoskin & Harcourt LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Osler, Hoskin & Harcourt LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions